NVIDIA and Eli Lilly unveiled a five-year, $1 billion collaboration to build an AI co‑innovation lab focused on drug discovery, committing compute and model development to accelerate in‑silico chemistry and biology. Jensen Huang and Lilly executives framed the lab as a hub to connect wet labs to computational models and scale AI-driven discovery workflows. In a parallel move, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to integrate NVIDIA’s AI infrastructure into scientific instruments and laboratory automation. Thermo Fisher will pair its instrument and software platforms with NVIDIA’s DGX and large models to reduce manual lab steps and speed analyses. Together, the agreements signal faster industry adoption of AI across R&D and lab operations and create commercial pathways for model-driven discovery and automated laboratory workflows.